KIR2DL3 antibody (FITC)

Catalog No. ABIN2661521

Product Details anti-KIR2DL3 Antibody (FITC)

Target: KIR2DL3 (Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 3 (KIR2DL3))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This KIR2DL3 antibody is conjugated to FITC

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.

Clone: DX27

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for KIR2DL3

Target: KIR2DL3 (Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 3 (KIR2DL3))

Alternative Name: CD158b (KIR2DL3 Products)

Synonyms: CD158B2 antibody, CD158b antibody, GL183 antibody, KIR-023GB antibody, KIR-K7b antibody, KIR-K7c antibody, KIRCL23 antibody, NKAT antibody, NKAT2 antibody, NKAT2A antibody, NKAT2B antibody, p58 antibody, killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 antibody, KIR2DL3 antibody

Background: CD158b is expressed on natural killer cells and a subset of T cells. It is a member of the immunoglobulin superfamily containing two immunoglobulin C2-type domains. Both variants and alternative isoforms of CD158b have been reported. The interaction of CD158b with specific HLA-C antigens on a target cell (HLA-Cw1, HLA-Cw3, HLA-Cw7 alleles, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK cell and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.

Pathways: Cancer Immune Checkpoints